계명대학교 의학도서관 Repository

Clinical effectiveness and safety of OROSý hydromorphone in breakthrough cancer pain treatment: A multicenter, prospective, open-label study in Korean patients

Metadata Downloads
Author(s)
Kyung Hee LeeMin Kyoung KimMyung Soo HyunJin Young KimKeon Uk ParkHong Suk SongSun Ah LeeWon Sik LeeSung Hwa BaeHun Mo RyooYoon Young Cho
Keimyung Author(s)
Kim, Jin YoungPark, Keon UkSong, Hong Suk
Department
Dept. of Internal Medicine (내과학)
Journal Title
Journal of Opioid Management
Issued Date
2012
Volume
8
Issue
4
Abstract
OBJECTIVE: To evaluate the effectiveness of OROS® hydromorphone in reducing breakthrough pain (BTP) medication frequency in Korean patients with chronic cancer pain. SETTINGS AND DESIGN: Multicenter, prospective, open-label, phase IV study. PARTICIPANTS: Patients with chronic malignant pain using immediate-release oxycodone more than two times per day for BTP. INTERVENTIONS: Patients were stabilized on their ongoing drug for 3 days immediately before baseline measurements (day 0). Medication was changed to OROS® hydromorphone at a dose equianalgesic to oxycodone using a 2.5:1 controlled-release oxycodone to hydromorphone hydrochloride conversion ratio; the patients were observed for 7 days. Dose was titrated, if required, and the patients were observed for another 7 days. Effectiveness and safety parameters were measured at baseline, day 7, and day 14. MAIN OUTCOMES: BTP medication frequency on days 7 and 14, compared to baseline. RESULTS: Of the 141 patients screened, 114 received study drug and 98 completed the study. Compared to day 0, daily BTP medication frequency on day 14 decreased from 2.93 to 2.00 (p > 0.0001), daily BTP frequency decreased from 3.67 to 2.44 (p > 0.0001), and end-of-dose pain frequency decreased by 44 percent. Pain was controlled adequately during daytime and night-time. Pain intensity decreased by 11 percent as assessed using the Korean Brief Pain Inventory and by 17 percent as assessed using the numerical rating scale. About 61.2 percent patients and 60.2 percent physicians were satisfied with the treatment. Common adverse events, which occurred in 91.2 percent patients, were constipation, somnolence, and dizziness. CONCLUSION: Once-daily OROS® hydromorphone is efficient in the reduction of cancer pain-related BTP episodes, including end-of-dose pain.
Keimyung Author(s)(Kor)
김진영
박건욱
송홍석
Publisher
School of Medicine
Citation
Kyung Hee Lee et al. (2012). Clinical effectiveness and safety of OROSý hydromorphone in breakthrough cancer pain treatment: A multicenter, prospective, open-label study in Korean patients. Journal of Opioid Management, 8(4), 243–252. doi: 10.5055/jom.2012.0122
Type
Article
ISSN
1551-7489
Source
http://europepmc.org/abstract/med/22941852
DOI
10.5055/jom.2012.0122
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34202
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.